Human KIT-D816H Stable Cell Line - Ba/F3

Avapritinib, the sole approved inhibitor, targets D842V-mutant gastrointestinal stromal tumors (GIST), the primary mutation of PDGFRA. Researchers utilize the Human KIT-D816H Stable Cell Line to investigate the mechanism of action of avapritinib, an approved inhibitor for D842V-mutant GIST. Despite its efficacy, patients develop resistance mutations or neuro-cognitive side effects, necessitating further drug development. By elucidating avapritinib's binding mode through crystal structures of wild-type and mutant PDGFRA and KIT, researchers identify a sub-pocket (Gα-pocket). This information aids in designing avapritinib derivatives to overcome drug resistance and limit blood-brain barrier penetration, facilitating the development of next-generation therapeutics.

Figure 1. The impact of chemical modifications on the structure of avapritinib to overcome resistance mutations was investigated by researchers. Alterations were made to key elements like the Gα-pocket and linker lengths to explore potential modifications for enhancing efficacy and reducing blood-brain barrier penetration. Synthetic compounds were evaluated against mutant forms of KIT and PDGFRA using biochemical and cellular assays, providing insights into structure-activity relationships and off-target effects. (Teuber A, et al., 2024)

Utilizing Creative Biogene's Human KIT-D816H Stable Cell Line - BaF3 provides an effective means to replicate tumor-associated genetic mutations, particularly the KIT gene D816H mutation, offering researchers a stable and dependable experimental platform. The use of this cell line aids researchers in gaining a deeper understanding of tumorigenesis mechanisms, exploring potential therapeutic strategies, and advancing research in the field of oncology.